14 results on '"Sato, Yuji"'
Search Results
2. Association of Estimated Total Body Iron with All-Cause Mortality in Japanese Hemodialysis Patients: The Miyazaki Dialysis Cohort Study.
- Author
-
Toida, Tatsunori, Sato, Yuji, Komatsu, Hiroyuki, and Fujimoto, Shouichi
- Abstract
Iron deficiency/excess may be associated with worse prognosis in patients undergoing hemodialysis. This study ascertained the association of the estimated total body iron (TBI) with mortality in patients receiving hemodialysis. Multicenter clinical data collected in the Miyazaki Dialysis Cohort Study from 943 patients receiving hemodialysis were analyzed after stratification into tertile categories by baseline TBI—estimated as the heme iron plus iron storage from ferritin levels. The primary outcome was a 5-year all-cause mortality; hazard ratios of the TBI–all-cause mortality association were estimated using Cox models adjusted for potential confounders, including clinical characteristics, laboratory, and drug data, wherein patients with high TBI were the reference category. The receiver operating characteristic (ROC) curve analyses of TBI, serum ferritin levels, and transferrin saturation were performed to predict all-cause mortality; a total of 232 patients died during the follow-up. The low TBI group (<1.6 g) had significantly higher hazard ratios of mortality than the high TBI group (≥2.0 g). As ROC curve analyses showed, TBI predicted mortality more accurately than either levels of serum ferritin or transferrin saturation. Lower TBI increases the mortality risk of Japanese hemodialysis patients, and further studies should examine whether iron supplementation therapy that avoids low TBI improves prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study
- Author
-
Hayashi, Matsuhiko, Abe, Takayuki, Iwai, Mieko, Matsui, Ayumi, Yoshida, Tadashi, Sato, Yuji, Kanno, Yoshihiko, and the Warfarin Study Group
- Published
- 2016
- Full Text
- View/download PDF
4. FP636PRE- AND POSTDIALYSIS URIC ACID DIFFERENCE AND RISK OF LONG-TERM ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN JAPANESE HEMODIALYSIS PATIENTS; MIYAZAKI DIALYSIS COHORT STUDY (MID STUDY)
- Author
-
Shouichi Fujimoto, Kazuo Kitamura, Hiroyuki Komatsu, Sato Yuji, and Tatsunori Toida
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,chemistry.chemical_compound ,chemistry ,Nephrology ,Internal medicine ,Uric acid ,Medicine ,Hemodialysis ,business ,All cause mortality ,Dialysis ,Cardiovascular mortality ,Cohort study - Published
- 2018
5. Pre- and Postdialysis Uric Acid Difference and Risk of Long-Term All-Cause and Cardiovascular Mortalities in Japanese Hemodialysis Patients; Miyazaki Dialysis Cohort Study.
- Author
-
Toida, Tatsunori, Sato, Yuji, Komatsu, Hiroyuki, Kitamura, Kazuo, and Fujimoto, Shouichi
- Subjects
- *
URIC acid , *HEMODIALYSIS patients , *COHORT analysis , *LONGITUDINAL method , *MORTALITY - Abstract
Background/Aims: Uric acid (UA) levels are affected by changes in dialysis; however, the relationship between the pre- and postdialysis UA difference (UAD) and mortality remains unclear. Methods: A total of 1,073 patients receiving maintenance hemodialysis (HD) were enrolled in this cohort study and followed up for 5 years. Patients were divided into quartile categories according to baseline UAD. Cox's regression analyses were used to investigate the relationship between UAD categories and all-cause and cardiovascular (CV) mortalities while adjusting for potential confounders. Results: A total of 280 patients died of all causes, including 121 CV deaths, during the follow-up. In the analysis for all-cause mortality, hazard ratios were significantly higher in the lowest UAD group (< 4.7 mg/dL) than in the highest UAD group (> 6.2 mg/dL). A correlation was not observed with CV mortality. Conclusion: UAD correlated with all-cause mortality. UAD may be the most appropriate reference for controlling UA in HD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Diminishing dry weight is strongly associated with all-cause mortality among long-term maintenance prevalent dialysis patients.
- Author
-
Sato, Yuji, Toida, Tatsunori, Nakagawa, Hideto, Iwakiri, Takashi, Nishizono, Ryuzoh, Kikuchi, Masao, and Fujimoto, Shouichi
- Subjects
- *
HEMODIALYSIS , *SYSTOLIC blood pressure , *MEDICAL sciences , *REGRESSION analysis ,CARDIOVASCULAR disease related mortality - Abstract
Objectives: To investigate the relationship between dry weight (DW) change and survival in long-term maintenance prevalent dialysis patients. Methods: We conducted a prospective data collection study with retrospective analysis of the registered data. Patients were followed up for 5 years (1-year observation of DW changes and subsequent 4-year follow-up). The outcome was all-cause mortality. The predictors were 1-year DW change rates. The hazard ratios (HRs) for all-cause mortality were calculated using multivariable Cox regression analysis, fully adjusted for age, sex, basal kidney disease, dialysis vintage, current smoking, past cardiovascular events, serum albumin, DW at enrollment, serum creatinine, mean predialysis systolic blood pressure, and cardiothoracic ratio or 1-year cardiothoracic ratio change rate. Propensity score (PS) analysis was also conducted using the same covariates of Cox regression analysis. Results: In total, 899 dialysis patients (mean dialysis vintage: 101.2 months) were followed up, and 180 deaths were recorded, of which 90 were of cardiovascular origin. Each 2% decrement of DW showed adjusted HR, and the 95% confidence interval was 1.24 [1.16–1.33]. According to the 1-year DW change rate, participants were divided into five groups (group A, ≥+3%; group B, +1 to +2.9%; group C, -0.9 to +0.9%; group D, -2.9 to -1.0%; and group E, ≤-3%). For survival curves based on grouping, group B had the best and group E had the worst survival rate (p<0.01, log-rank test). Therefore, we set group B as a reference; adjusted risks for death of groups D and E were 2.16 [1.23–3.79] and 2.66 [1.54–4.58], respectively. However, this relation was blunted in patients of heavier DW. The PS-matched cohort showed a poorer prognosis in patients with diminishing DW divided by DW change rate at -0.635% (mean value of DW change rate). Conclusion: In the long-term maintenance hemodialysis cohort, 1-year DW decrement, especially ≤-3.0%, was significantly associated with all-cause mortality, and cardiovascular disease-related death was prominent in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Risk of Cerebral Infarction in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study (MID study).
- Author
-
Toida, Tatsunori, Sato, Yuji, Nakagawa, Hideto, Komatsu, Hiroyuki, Uezono, Shigehiro, Yamada, Kazuhiro, Ishihara, Tabito, Hisanaga, Shuichi, Kitamura, Kazuo, and Fujimoto, Shouichi
- Subjects
- *
ANTICOAGULANTS , *HEMODIALYSIS patients , *JAPANESE people , *CEREBRAL infarction , *ATRIAL fibrillation , *PLATELET aggregation inhibitors , *DISEASES - Abstract
Background/Aims: Predictors including the preventive effects of antiplatelet and anticoagulant drugs on cerebral infarction (CI) events have not yet been clarified in dialysis patients. The aim of the present study was to examine the risk of CI and preventive effects of these drugs in Japanese hemodialysis patients. Methods: Patients receiving maintenance hemodialysis (n=1,551, median age (interquartile range), 69.0 (59.0-78.0) years; 41.5% female) were enrolled in the Miyazaki Dialysis Cohort Study and prospectively followed-up for 3 years. Kaplan-Meier and Cox's regression analyses were used to clarify the risk of CI. Results: Eightyfour patients developed CI at an incidence of 21.5/1000 patients per year. The presence of a previous history of CI, atrial fibrillation (AF), and diabetes mellitus in addition to age were also identified as predictive factors for new CI, whereas no relationship was observed between antiplatelet and/or anticoagulant usage and CI. Furthermore, no significant difference was noted in the frequency of CI events between patients with AF who received warfarin and those who did not. Conclusions: The incidence of CI was higher in dialysis patients with a previous history of CI and AF; however, the preventive effects of antiplatelet/anticoagulant drugs on the development of CI were not evident. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. A Randomized Control Study on the Procedure for Switching Epoetin Beta (EPO) to Epoetin Beta Pegol (CERA) in the Treatment of Renal Anemia in Maintenance Hemodialysis Patients.
- Author
-
Toida, Tatsunori, Sato, Yuji, Shibata, Norihiko, Kitamura, Kazuo, and Fujimoto, Shouichi
- Subjects
- *
HEMODIALYSIS patients , *RENAL anemia , *ACUTE kidney failure , *ANEMIA , *DRUG administration , *THERAPEUTICS - Abstract
Background/Aims: We investigated the method of switching EPO to CERA that does not cause a decrease in the Hb level. Methods: Fifty EPO-treated patients were randomly divided into two groups in which CERA was administered every two weeks (Q2W) or every four weeks (Q4W). After 8 weeks of treatment, the frequency of administration was changed to Q4W in the former. Follow-up was performed for 24 weeks. Results: There was no difference in the Hb level between the two groups until 6 weeks. In the Q2W group, the Hb maintained a stable level throughout a study period. However, in the Q4W group, the Hb level was significantly lower than in the Q2W group at weeks 9, 11, and 13. Conclusion: EPO switching to CERA without a decrease in the Hb level could be achieved by administering CERA every two weeks, but not every four weeks, for a specific period after switching. © 2014 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. A case–control study of calciphylaxis in Japanese end-stage renal disease patients.
- Author
-
Hayashi, Matsuhiko, Takamatsu, Ichiro, Kanno, Yoshihiko, Yoshida, Tadashi, Abe, Takayuki, and Sato, Yuji
- Subjects
CALCIPHYLAXIS ,CHRONIC kidney failure ,JAPANESE people ,DISEASE complications ,SKIN diseases ,HEMODIALYSIS ,CASE-control method ,PATIENTS ,DISEASES - Abstract
Background. Calciphylaxis, also called calcific uremic arteriolopathy, is a rare and often fatal complication of end-stage renal disease and is characterized by painful skin ulceration, necrosis, medial calcification and intimal proliferation of small arteries. Studies in western countries have reported incidences ranging from 1 to 4% in chronic hemodialysis patients. Since no systematic studies of calciphylaxis have ever been performed in Japan, we conducted a nationwide survey and a case–control study to identify the characteristics of calciphylaxis in the Japanese dialysis population.Methods. Firstly, we sent a questionnaire to 3760 hemodialysis centers in Japan, asking whether calciphylaxis cases had been encountered in the past, and detailed clinical data regarding each case were then collected from the centers. In addition, two control dialysis patients matched for age and duration of hemodialysis to each calciphylaxis case were identified at the participating centers, and their data were analyzed to identify risk factors for calciphylaxis.Results. Responses to the questionnaire were obtained from 1838 centers (48.3%), and 151 centers reported that a total of 249 cases had been encountered. Sixty-four centers agreed to participate in the case–control study, and detailed clinical data in regard to 67 cases were obtained. In 28 of the 67 cases, a definite diagnosis of calciphylaxis was made by our study group based on the clinical characteristics and skin biopsy findings. A univariate logistic regression model comparing them with 56-matched controls identified warfarin therapy [odds ratio (OR) 11.4, 95% confidence interval (CI)] 2.7–48.1, P = 0.0009], each 1 g/dL decline in serum albumin level (OR 19.8, 95% CI 4.4–89.5, P = 0.0001), each 100 mg/dL increment in plasma glucose level (OR 3.74, 95% CI 1.08–12.9, P = 0.037) and each 1 mg/dL increment in adjusted serum calcium level (OR 3.2, 95% CI 1.63–6.30, P = 0.0008) at the time of diagnosis as significantly associated with calciphylaxis, but no significant associations were found with female gender, vitamin D analog therapy, serum phosphate level, adjusted calcium–phosphate products or serum alkaline–phosphatase level. Warfarin therapy and lower serum albumin levels were still significant risk factors after a multivariate logistic regression model analysis.Conclusion. The results of this study showed that warfarin therapy and lower serum albumin levels are significant and strong risk factors for the development of calciphylaxis in chronic hemodialysis patients in Japan. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
10. Radial Augmentation Index is Related to Cardiovascular Risk in Hemodialysis Patients.
- Author
-
Nishiura, Ryosuke, Kita, Toshihiro, Yamada, Kazuhiro, Komatsu, Hiroyuki, Hara, Seiichiro, Sato, Yuji, and Fujimoto, Shouichi
- Abstract
Cardiovascular accidents related to atherosclerosis are the leading cause of death among hemodialysis patients, which makes continuous monitoring of their cardiovascular status crucial. Recently, a handy device for monitoring the augmentation index (AIx) in the radial artery was introduced in Japan, enabling the use of the AIx in addition to pulse wave velocity (PWV) in the management of hemodialysis patients. In this study the AIx, PWV, abdominal aortic calcification index (ACI), and left ventricular mass index (LVMI) were serially assessed in 108 hemodialysis patients. The radial AIx was monitored using a newly introduced tonometer (HEM-9010AI), and the interrelationships among the measured parameters and their contributions to the risk of cardiovascular accidents were evaluated. The radial AIx was significantly higher in hemodialysis patients than in healthy subjects ( N = 50) and was well correlated with risk markers such as LVMI ( r = 0.30, P = 0.019) and ACI ( r = 0.38, P < 0.001), but not with PWV. Multiregression analysis showed that radial AIx was also significantly associated with LVMI, ACI and blood pressure; PWV was associated with other parameters such as age, blood pressure, and ACI. The AIx and ACI were both significantly increased in patients with cardiovascular complications. Although PWV was strongly increased in the hemodialysis patients, it failed to discriminate between these subgroups of high-risk patients. The radial AIx is closely associated with aortic calcification, cardiac hypertrophy, and a history of cardiovascular accidents in hemodialysis patients, and could be a useful marker for management of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
11. Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis.
- Author
-
Yamada, Kazuhiro, Fujimoto, Shouichi, Nishiura, Ryosuke, Komatsu, Hiroyuki, Tatsumoto, Mariko, Sato, Yuji, Hara, Seiichiro, Hisanaga, Shuichi, Ochiai, Hideyuki, Nakao, Hiroyuki, and Eto, Tanenao
- Subjects
CALCIUM ,C-reactive protein ,HEMODIALYSIS ,SERUM ,PATIENTS - Abstract
Background. Vascular calcification is an independent determinant of cardiovascular events in maintenance haemodialysis (HD) patients. It is not known whether acute changes of the serum calcium concentration before and after HD (▵Ca) are associated with the development of aortic calcification. [ABSTRACT FROM PUBLISHER]
- Published
- 2007
- Full Text
- View/download PDF
12. Effect of Sevelamer on Dyslipidemia and Chronic Inflammation in Maintenance Hemodialysis Patients.
- Author
-
Yamada, Kazuhiro, Fujimoto, Shouichi, Tokura, Takeshi, Fukudome, Keiichi, Ochiai, Hideyuki, Komatsu, Hiroyuki, Sato, Yuji, Hara, Seiichiro, and Eto, Tanenao
- Subjects
HEMODIALYSIS patients ,INFLAMMATION ,CARDIOVASCULAR diseases ,DISEASES ,BLOOD filtration ,KIDNEY diseases ,PATIENTS - Abstract
Background: Hemodialysis (HD) patients often experience cardiovascular events, that might be related to altered calcium–phosphate metabolism, dyslipidemia, and chronic inflammation in addition to hypertension. Sevelamer, a non-calcium-containing phosphate binder, may improve the lipid profile of HD patients. However, the influence of sevelamer on chronic inflammation has not been clarified. Methods: We enrolled 36 maintenance HD patients with a serum calcium (Ca) or phosphate (P) level constantly greater than 9.5 mg/dL and 5.5 mg/dL, respectively. The dose of sevelamer was titrated to achieve a serum Ca and P in the target ranges. The study period was 24 weeks. Patients underwent the following measurements: bone mineral markers, lipids, and a high-sensitivity C-reactive protein (hs-CRP). Results: In the 28 patients who completed the study, sevelamer significantly reduced the mean non-high-density lipoprotein cholesterol (non-HDL-C) level by 15% and 20% ( p [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
13. Association between Serum Zinc Levels and Clinical Index or the Body Composition in Incident Hemodialysis Patients.
- Author
-
Toida, Tatsunori, Toida, Reiko, Ebihara, Shou, Takahashi, Risa, Komatsu, Hiroyuki, Uezono, Shigehiro, Sato, Yuji, and Fujimoto, Shouichi
- Abstract
Background: The relationships between serum zinc levels and body composition or clinical outcomes of incident hemodialysis (HD) patients remain unclear. Methods: This prospective observational study examined the relationships between serum zinc levels and clinical indexes, including body composition, in 142 incident HD patients using a bioelectrical impedance analysis. Patients were divided into three groups according to baseline serum zinc levels: tertile, <45, 45–59, and ≥60 µg/dL. The reference group was set as ≥60 µg/dL. Cox's regression analysis was performed to investigate the relationships between serum zinc categories and cardiovascular events and all-cause mortality after adjustments for potential confounders. Results: Serum zinc levels positively correlated with the nutritional index and negatively correlated with fluid volume markers. In a mean follow-up of 2.5 years, there were 20 cases of cardiovascular events and 15 of all-cause mortality. In the Cox's regression analysis for cardiovascular events and all-cause mortality, the hazard ratio increased with a decrease in serum zinc levels, but was not significant. Conclusion: Serum zinc levels were associated with nutritional and fluid volume markers in incident HD patients. To clarify the relationship between serum zinc levels and cardiovascular events or mortality, further studies with a larger number of cases will be necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report.
- Author
-
Nishizono, Ryuzoh, Kogou, Hiroki, Ishizaki, Yuri, Minakawa, Akihiro, Kikuchi, Masao, Inagaki, Hiroko, Sato, Yuji, and Fujimoto, Shouichi
- Subjects
TYPE 1 diabetes ,NEPHROTIC syndrome ,DIABETIC nephropathies ,JAPANESE women ,DIABETIC acidosis ,SERODIAGNOSIS ,THERAPEUTIC use of glucocorticoids ,KIDNEY disease treatments ,INSULIN therapy ,BIOPSY ,PREDNISOLONE ,HYPOGLYCEMIC agents ,KIDNEY diseases ,HEMAPHERESIS ,HEMODIALYSIS ,KIDNEY glomerulus ,DISEASE complications - Abstract
Background: Concurrent type 1 diabetes mellitus (T1DM) and idiopathic nephrotic syndrome is rare, and most previously reported cases were in children. We report the case of an adult woman who developed T1DM and minimal change nephrotic syndrome (MCNS) nearly simultaneously.Case Presentation: A 24-year-old woman had first presented to another hospital with nausea, vomiting, and fatigue. She was diagnosed with diabetic ketoacidosis and T1DM on the basis of her hyperglycemia, ketoacidosis, and positive anti-glutamic acid decarboxylase antibody test result. Rapid infusion of normal saline and insulin administration alleviated hyperglycemia and ketoacidosis. Two weeks after admission, however, she developed nephrotic syndrome (NS) with rapidly decreasing urine volume. She was referred to our hospital with a diagnosis of acute kidney injury. Although she temporarily required dialysis and high doses of insulin, within 1 month NS and acute kidney injury had been alleviated by oral prednisolone and low-density lipoprotein apheresis. Renal biopsy showed minor glomerular abnormalities without diabetic nephropathy, so we diagnosed her with MCNS. Seven weeks after the discharge, NS relapsed, and cyclosporine was added to prednisolone. However, NS relapsed twice within the next 4 months, so we started her on rituximab. At 6 months after initiating rituximab therapy, she remained in complete remission. Her mother also had T1DM but not MCNS. The patient had HLA-DRB1*09:01/09:01, DQB1*03:03/03:03, and her mother had HLA-DRB1*04:05/09:01, DQB1*03:03/04:01.Conclusions: Concurrent T1DM and MCNS is rare and their coexistence might be coincidental. Alternatively, they might have been caused by an underlying, unidentified genetic predisposition. Previous reports and our patient's findings suggest that specific HLA alleles and haplotypes or a Th1/Th2 imbalance might be associated with T1DM and MCNS that occurred nearly simultaneously. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.